Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

996 questions · 1,049 findings · 79 reviews · Dementia and Cognitive Improvement

No studies found 240 · 22.9%GRADE not reported 31 · 3%Very low 216 · 20.6%Low 253 · 24.1%Moderate 238 · 22.7%High 71 · 6.8%

Cannabinoids vs placebo

Behavioural and psychological symptoms of dementia (BPSD) · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review

Cannabinoids vs placebo

Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review

Cannabinoids vs placebo

Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity

Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).

1 finding from 1 review